Combining a Web3 IP market, venture capital, and a decentralized autonomous organization (DAO), three companies have banded together to create a new decentralized science ecosystem. The full press release is included here.
Feb. 21, 2022, Switzerland — Molecule, a biotech IP Web3 marketplace, announces a tripartite partnership with Apollo Health Ventures, a leading longevity-focused venture capital fund, and VitaDAO, a decentralized autonomous organization funding early-stage longevity biotech (“LongBio”) R&D.
VitaDAO and Molecule collaboratively source geroscience assets and finance R&D at universities, institutes, and biotech companies. VitaDAO has a worldwide network of >3,000 community members engaged in sourcing and evaluating early stage longevity biotech assets. Apollo and VitaDAO will collaborate on financing and building the LongBio ecosystem. By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem.
There are inefficiencies in biopharma R&D and university tech transfer that new Web3 marketplace tools will address. Molecule has pioneered a new type of liquid asset class, the IP-NFT (a non fungible token that holds intellectual property) that is one such tool. With new forms of governance via DAOs, such as VitaDAO, and valuation of IP, such as IP-NFTs, moves early-stage intellectual property into Web3 to allow for greater liquidity, discoverability, and reduced legal complexity by standardizing licensing terms.
About Apollo Health Ventures
Apollo Health Ventures is a transatlantic venture capital firm specialized in developing and investing in data-driven biotechnology and health tech ventures. Apollo Health Ventures invests in game-changing companies at the seed or early stage and builds companies within the aging sector. Apollo’s team consists of entrepreneurs, seasoned biotech investors and scientists with remarkable track records in life science investments and venture creation.
Molecule is a decentralized biotech protocol building a web3 marketplace for research-related IP and scalable frameworks to build biotech DAOs. They enable quick and easy funding for academics and biotech companies globally, while enabling patient, researcher, and investor communities to directly fund, govern, and own research-related IP. Molecule democratizes biopharma research and development.
VitaDAO is a DAO collective for community-governed, decentralized drug development. Its core mission is the acceleration of research and development (R&D) in the longevity space and the extension of human life and healthspan. To achieve this, VitaDAO funds and digitizes research and the resulting assets using IP-NFTs and other innovative financialization approaches.
For media enquiries, contact:
Apollo Health Ventures Socials: